JPS5843926A - 選択性制癌剤 - Google Patents

選択性制癌剤

Info

Publication number
JPS5843926A
JPS5843926A JP56142158A JP14215881A JPS5843926A JP S5843926 A JPS5843926 A JP S5843926A JP 56142158 A JP56142158 A JP 56142158A JP 14215881 A JP14215881 A JP 14215881A JP S5843926 A JPS5843926 A JP S5843926A
Authority
JP
Japan
Prior art keywords
cells
drug
human
conjugate
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP56142158A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0259128B2 (enExample
Inventor
Toshihiro Nakanishi
俊博 中西
Hajime Yoshizumi
肇 吉栖
Kozo Imai
浩三 今井
Akira Taniuchi
昭 谷内
Fueroone Sorudano
ソルダノ・フエロ−ネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suntory Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Priority to JP56142158A priority Critical patent/JPS5843926A/ja
Priority to PCT/JP1982/000356 priority patent/WO1983000810A1/ja
Priority to EP82304730A priority patent/EP0074279B1/en
Publication of JPS5843926A publication Critical patent/JPS5843926A/ja
Publication of JPH0259128B2 publication Critical patent/JPH0259128B2/ja
Priority to JP3323772A priority patent/JPH06157346A/ja
Priority to JP3323773A priority patent/JPH06157347A/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
JP56142158A 1981-09-08 1981-09-08 選択性制癌剤 Granted JPS5843926A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP56142158A JPS5843926A (ja) 1981-09-08 1981-09-08 選択性制癌剤
PCT/JP1982/000356 WO1983000810A1 (fr) 1981-09-08 1982-09-07 Agent carcinostatique selectif
EP82304730A EP0074279B1 (en) 1981-09-08 1982-09-08 Selective anti-tumour agents
JP3323772A JPH06157346A (ja) 1981-09-08 1991-11-11 選択性制癌剤
JP3323773A JPH06157347A (ja) 1981-09-08 1991-11-11 選択性制癌剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56142158A JPS5843926A (ja) 1981-09-08 1981-09-08 選択性制癌剤

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP3323773A Division JPH06157347A (ja) 1981-09-08 1991-11-11 選択性制癌剤
JP3323772A Division JPH06157346A (ja) 1981-09-08 1991-11-11 選択性制癌剤

Publications (2)

Publication Number Publication Date
JPS5843926A true JPS5843926A (ja) 1983-03-14
JPH0259128B2 JPH0259128B2 (enExample) 1990-12-11

Family

ID=15308705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56142158A Granted JPS5843926A (ja) 1981-09-08 1981-09-08 選択性制癌剤

Country Status (3)

Country Link
EP (1) EP0074279B1 (enExample)
JP (1) JPS5843926A (enExample)
WO (1) WO1983000810A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPS6136229A (ja) * 1984-07-30 1986-02-20 Kayaku:Kk 選択的制癌物質
JPS62181280A (ja) * 1985-10-17 1987-08-08 ネオルツクス　コ−ポレイシヨン トリコテセン結合体を含む抗腫瘍剤
JPS63115827A (ja) * 1986-06-30 1988-05-20 オンコ−ゲン 新規な免疫結合体およびその腫瘍療法における使用
JPH03504556A (ja) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ‐１を中和するモノクローナル抗体
JPH05279400A (ja) * 1984-02-08 1993-10-26 Cetus Corp ヒト乳癌細胞に対するモノクローナル抗体と細胞毒性成分とのイムノトキシン
JP2651046B2 (ja) * 1990-10-12 1997-09-10 アメリカ合衆国 マウスモノクローナル抗体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
US4500637A (en) * 1982-07-19 1985-02-19 The United States Of America As Represented By The Department Of Health And Human Services Prevention of graft versus host disease following bone marrow transplantation
GB2131830A (en) * 1982-12-10 1984-06-27 Ludwig Inst Cancer Res Monoclonal antibody for use against breast cancer
FR2546756B1 (fr) * 1983-06-03 1985-11-29 Centre Nat Rech Scient Nouveaux derives immunostimulants, leur preparation et leur application comme medicament
FR2566271B1 (fr) * 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
PT80662B (en) * 1984-06-20 1986-12-09 Sanofi Sa Process to obtain anti-tumoral glycoprotein modified on its glycidic portions
FR2577137B1 (fr) * 1985-02-13 1990-07-13 Sanofi Sa Glycoproteines antitumorales, modifiees sur leurs motifs glucidiques
CA1339798C (en) * 1985-02-01 1998-04-07 Alan N. Houghton Method for treatment of neuroectodermal malignancies and epithelial carcinomas in humans
FR2577135B1 (fr) * 1985-02-13 1989-12-15 Sanofi Sa Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques
US5405966A (en) * 1985-10-17 1995-04-11 Theodore; Louis J. Trichothecene conjugates
CA1289880C (en) * 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
DE3685485D1 (de) * 1985-12-06 1992-07-02 Cetus Corp Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung.
FR2602683B1 (fr) * 1986-08-12 1990-03-30 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant une glycoproteine inhibant les ribosomes, modifiee par oxydation des motifs osidiques puis reduction
FR2591895B1 (fr) * 1985-12-20 1988-08-26 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
US4911912A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein
US4911911A (en) * 1985-12-20 1990-03-27 Sanofi Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
FR2591894B1 (fr) * 1985-12-20 1988-04-01 Sanofi Sa Immunotoxines a longue duree d'action in vivo comportant la chaine a de ricine modifiee sur ses motifs polysaccharidiques
US4699784A (en) * 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
FR2601679B1 (fr) * 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
DE3820452A1 (de) * 1988-06-13 1989-12-14 Schering Ag Verfahren zur bildlichen darstellung von tumoren unter verwendung von monoklonalen antikoerpern
CA2021942C (en) * 1989-08-10 2001-04-10 Michel Page Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
DE10328121A1 (de) * 2003-06-23 2005-02-03 Biolife Science Forschungs- und Entwicklungs-GbmH Passive Immuntherapie gegen malignes Melanom
US8318162B2 (en) 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748924A (en) * 1980-07-14 1982-03-20 Univ California Antibody target cell injuring agent
JPS57179124A (en) * 1981-04-15 1982-11-04 Sanofi Sa Anticancer and preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55136235A (en) * 1979-04-09 1980-10-23 Teijin Ltd Antitumor protein complex and its preparation
JPS5616418A (en) * 1979-07-20 1981-02-17 Teijin Ltd Antitumor protein complex and its preparation
JPS57106626A (en) * 1980-12-22 1982-07-02 Teijin Ltd Cytotoxic protein complex and its preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748924A (en) * 1980-07-14 1982-03-20 Univ California Antibody target cell injuring agent
JPS57179124A (en) * 1981-04-15 1982-11-04 Sanofi Sa Anticancer and preparation

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58118520A (ja) * 1982-01-09 1983-07-14 Hidematsu Hirai 抗腫瘍性蛋白複合体およびその製造法
JPH05279400A (ja) * 1984-02-08 1993-10-26 Cetus Corp ヒト乳癌細胞に対するモノクローナル抗体と細胞毒性成分とのイムノトキシン
JPS6136229A (ja) * 1984-07-30 1986-02-20 Kayaku:Kk 選択的制癌物質
JPS62181280A (ja) * 1985-10-17 1987-08-08 ネオルツクス　コ−ポレイシヨン トリコテセン結合体を含む抗腫瘍剤
JPS63115827A (ja) * 1986-06-30 1988-05-20 オンコ−ゲン 新規な免疫結合体およびその腫瘍療法における使用
JPH03504556A (ja) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ‐１を中和するモノクローナル抗体
JP2651046B2 (ja) * 1990-10-12 1997-09-10 アメリカ合衆国 マウスモノクローナル抗体

Also Published As

Publication number Publication date
WO1983000810A1 (fr) 1983-03-17
EP0074279A2 (en) 1983-03-16
EP0074279B1 (en) 1987-08-12
EP0074279A3 (en) 1984-03-21
JPH0259128B2 (enExample) 1990-12-11

Similar Documents

Publication Publication Date Title
JPS5843926A (ja) 選択性制癌剤
US7033572B2 (en) Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
JP3040121B2 (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
CA1301066C (en) Anti-tumour substance and process for producing the same
JPS635033A (ja) 化合物標的化組成物
JPS6270377A (ja) ハプテンで修飾された診断薬および治療薬の抗体コンプレツクス
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
JPH10506881A (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
JP3340127B2 (ja) 異常増殖性疾患措置のための抗体接合体
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
TW201905000A (zh) 含有抗globo h抗體之抗體－藥物共軛物及其用途
JP2002509158A (ja) アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
EP0288520B1 (en) Use and composition for improved targeting of antibody, antibody fragments, and conjugates thereof
JPH08501059A (ja) Ｃｄ３３関連表面抗原に対する免疫毒素
JPH05503098A (ja) セプシスの処理のためのサイトカイン抗体
EP0596011A1 (en) Trifunctional compounds having specificity for multi-drug resistant cells
JPH05500953A (ja) 免疫共役体およびその代謝物の非標的保持量を減少させる方法
CN116981695A (zh) 含工程化铰链区的抗体及其应用
JPH01502195A (ja) 細胞毒性結合物の増強法
Li et al. Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity
CA1202897A (en) Selective antitumor agent
JPH06157347A (ja) 選択性制癌剤
JPH06157346A (ja) 選択性制癌剤
Arnon Department of Chemical Immunology
CN116925220A (zh) Il20rb中和抗体及其医药用途